arbiter
JournalsPricingAccount

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation

Rubén Queiro et al.

Expert Review of Pharmacoeconomics & Outcomes Research2026https://doi.org/10.1080/14737167.2026.2629351article
ABDC C
Weight
0.50

What the paper says

Ixekizumab, tofacitinib, and golimumab are all cost-effective options for PsA. These findings support phenotype-guided therapeutic decisions and highlight the influence of drug pricing.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1080/14737167.2026.2629351

Or copy a formatted citation

@article{rubén2026,
  title        = {{Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation}},
  author       = {Rubén Queiro et al.},
  journal      = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1080/14737167.2026.2629351},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.